Indication

Autoimmune Adverse Effects of Anti-neoplastic Drug

1 clinical trial

Clinical trial

Autoantibodies Prevalence and Their Related-diseases During Checkpoint Inhibitor Treatment

Status: Active (not recruiting), Estimated PCD: 2024-01-15